AI model could spare diabetes patients from invasive kidney biopsies
NCT ID NCT07672639
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study uses machine learning to tell apart diabetic kidney disease from other kidney diseases in people with type 2 diabetes. Researchers analyzed data from over 2,200 patients across 14 medical centers to build a model that uses routine clinical and lab information. The goal is to provide a noninvasive way to diagnose kidney problems, potentially avoiding the need for a kidney biopsy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a noninvasive way to diagnose kidney disease in diabetes patients, reducing the need for risky biopsies.
- What could go wrong
- This is a retrospective study using existing data, so results may not apply to all populations. The model's accuracy depends on data quality and may not replace biopsy in all cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
2,201 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consisted of adults aged 18-70 years with type 2 diabetes mellitus who underwent clinically indicated kidney biopsy at 14 medical centers in China. Participants were identified retrospectively from biopsy records between January 2019 and December 2022. Patients with definitive pathological diagnoses of diabetic kidney disease (DKD) or non-diabetic kidney disease (NDKD) and available clinical data were included in model development. An independent cohort of biopsy-confirmed patients enrolled between January 2022 and December 2024 was used for external validation.
- Ages
-
18 to 70 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-70 years * Diagnosis of type 2 diabetes mellitus according to ADA criteria * Underwent kidney biopsy * Definitive pathological diagnosis available * Availability of required clinical and laboratory data Exclusion Criteria: * Type 1 diabetes mellitus * Secondary diabetes * Missing key clinical data * Non-diagnostic kidney biopsy * Incomplete pathological information
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Can a Patient's own kidney cells hold off dialysis?
- Tiny horses, big lessons: can ponies help kids tame diabetes?